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Accepted 7 November 2018Objectives: To compare uterine rupture rates in women having a medical abortion receiving gemeprost alone to
those receiving mifepristone plus gemeprost.
Study design:We reviewed the records ofwomen undergoingmedical abortion at 13 0/7–23 6/7weeks from Jan-
uary 2007 to December 2014 at a single center in Italy. Prior to January 2011, we used gemeprost 1 mg vaginally
every 3 h up to a maximum of ﬁve doses. After January 2011, we addedmifepristone 200 mg orally 24 h prior to
the same gemeprost protocol. The primary outcome of the study was the incidence of uterine rupture. We
compared the outcome between women receiving gemeprost alone with the combination of gemeprost and
mifepristone.
Results: One thousand and sixty-one (58.5%) and 753 (41.5%) women underwent medical abortion in the
gemeprost-alone and the gemeprost/mifepristone groups, respectively. Five (0.47%) uterine ruptures occurred
in the gemeprost and four uterine ruptures occurred in the gemeprost/mifepristone groups, respectively
(0.53%) (p=.89). All uterine ruptures occurred in women with prior cesarean delivery.
Conclusions:We rep orted no difference in the incidence of uterine rupture between the gemeprost-alone and
gemeprost and mifepristone groups.
Implications: Uterine rupture is a rare complication of second-trimester medical abortion with gemeprost. Use of
mifepristone prior to gemeprost does not affect this risk.
© 2018 Elsevier Inc. All rights reserved.Keywords:
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Women can choose to have second-trimester abortion by medical
induction or standard dilation and evacuation (D&E). Providers perform
D&E more commonly in the United States, while in Europe, providers
usemifepristone and a prostaglandin analogue to induce abortionmed-
ically [1–3].
Second-trimester abortion is extremely safe, and complications are
uncommon [4].While the incidence of complications is very low, bleed-
ing and cervical trauma are most common, with uterine rupture and
perforation being rare [5,6]. The presence of a uterine scar from one or
more prior cesarean deliveries is an important risk factor for uterine
rupture [7–13]. Two systematic reviews on second-trimester abortion
with misoprostol support the ﬁnding that previous cesarean section is
a risk factor for uterine rupture during abortion, with an absolute risk.
for this study.
. Saccone).of 0.4%, 10 times higher than in women with an intact uterus [13,14].
Previous studies suggest that gemeprost use for second-trimester
medical abortion results in a higher risk of uterine rupture than
misoprostol [15].
The commonly used second-trimester abortion regimen is mifepris-
tone combinedwith a prostaglandin analogue. This regimen reduces the
induction–abortion interval by 50%; however, few data exist on this
regimen's impact on risk of uterine rupture [4,16–19].
We aim to compare uterine rupture rates between women having
a medical abortion with gemeprost alone and mifepristone plus
gemeprost.
2. Materials and methods
We reviewed charts of pregnantwomen at 13 0/7 to 23 6/7weeks of
gestation undergoingmedical abortion from January 2007 to December
2014 at University of Naples Federico II, Naples, Italy, and prospectively
entered the data into a deidentiﬁed database.
We included women with a viable singleton pregnancy between 13
and 24 weeks with an indication for second-trimester abortion allowed
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when the life of women would be at risk if the pregnancy is carried to
term or if the fetus carries genetic or other serious malformations
whichwould put themother at risk of serious psychological or physical
consequences. We only included women who had an abortion per-
formed according to our standard protocol to make accurate between-
group comparisons.
From 2007 to 2010, we used gemeprost 1 mg vaginally (Cervidil®,
Merck Serono, Italy), the only drug licensed for this indication in Italy,
every 3 h up to a maximum of ﬁve doses or until fetal expulsion. In
womenwith prior cesarean delivery, we interrupted gemeprost admin-
istration as soon as labor started. If abortion had not occurredwithin the
ﬁrst 24 h, we offered a washout period of 1 day, and we administered
gemeprost 1 mg vaginally again every 3 h up to a maximum of ﬁve
doses. We deﬁned a failed induction abortion as absence of fetal expul-
sion after three induction cycles. We performed D&E in case of failed in-
duction. After 2011, we offered a single dose of mifepristone 200 mg
orally (Mifegyne®, Exelgyn, France) 24–72 h before prostaglandin ad-
ministration [2,18].
We administered oxytocin 10 IU intravenously (Syntocinon®,
Novartis, Italy) and/or ergometrine 0.5 mg intramuscularly
(Methergin®, Novartis, Italy) following expulsion of the fetus and pla-
centa. We performed curettage of the uterus for retained placenta or
suspicion of incomplete abortion documented during routine ultra-
sound after the abortion.
The incidence of uterine rupture is the primary outcome of the
study. We deﬁned uterine rupture as a disruption or tear of the uterine
muscle and visceral peritoneum, or separation of the uterine muscle
with extension to bladder or broad ligament. We conﬁrmed clinically
suspected uterine rupture at the time of laparotomy. The secondary
outcome is the incidence of hysterectomy. We compared primary
and secondary outcomes between women receiving gemeprost
alone and those receiving gemeprost and mifepristone. We also per-
formed a subgroup analysis of outcomes in women with prior cesarean
delivery.
We performed statistical analysis was using Statistical Package for
Social Sciences (SPSS) v. 19.0 (IBM Inc., Armonk, NY, USA). We com-
pared univariate dichotomous data with the χ2 or Fisher’s Exact Test.
We used the Mann–Whitney U test to make comparisons between
groups.
We considered two-sided p values b.05 statistically signiﬁcant.3. Results
From 2007 to 2014, 1838 women had second-trimester medical
abortion in our department (Table 1). We excluded 24 patients for
lack of adherence to the standard protocol. Among the remaining
1814 cases, 1061 (58.5%) received gemeprost alone, and 753 (41.5%) re-
ceived mifepristone and gemeprost.Table 1
Characteristics of second-trimester medical abortion patients at University of Naples
Federico II from 2007 to 2014
Gemeprost
alone,
n=1061
Gemeprost +
Mifepristone,
n=753
p
value
Maternal age 32.4±6.5 32.7±6.3 .32
Gestational age at abortion 19.7±2.9 19.8±3.2 .50
Body mass index 23.3±5.4 23.7±4.1 .07
Smoking 210 (19.8%) 161 (21.4%) .61
Race .63
Caucasian 980 (92.4%) 700 (93.0%)
Other 81 (7.6%) 53 (7.0%)
Prior cesarean delivery 160 (15.1%) 180 (23.9%) b.01
Data are presented as mean±standard deviation or as number (percentage).Overall, 340women (18.7%) had one ormore prior cesarean deliver-
ies: 160 (15.1%) in the gemeprost-alone and 180 (23.9%) in the mifep-
ristone and gemeprost group, respectively.
In our cohort, all nine uterine ruptures (9/1814; 0.5%) occurred in
women with prior cesarean delivery. The incidence of uterine rupture
in the cesarean delivery group was 2.6% (9/340). We reported annual
number of second-trimester medical abortions and number of patients
with prior cesarean delivery, uterine rupture and hysterectomy in
Table 2.
Five uterine ruptures occurred in the gemeprost-alone group (5/
1061; 0.47%), and four in the mifepristone and gemeprost group (4/
753; 0.53%) (p=.89).
We report details of the uterine rupture cases in Table 3. All cases in
which the surgeons suspected uterine rupture did have rupture con-
ﬁrmed at laparotomy, two of which resulted in hysterectomy to control
blood loss.We repaired the uterus in the remaining seven caseswithout
the need for any additional procedures. Nomaternal deaths occurred in
the study cohort.4. Discussion
This retrospective study evaluated the incidence of uterine rupture
in women undergoing second-trimester medical abortion.We reported
an overall rate of uterine rupture of 0.5% (9/1814). In the subgroup anal-
ysis of women with prior cesarean delivery, the incidence of uterine
rupture was 2.6% (9/340). In women with prior cesarean delivery, we
reported no statistically signiﬁcant difference in the incidence of uterine
rupture in the gemeprost-alone or mifepristone and gemeprost groups.
The retrospective nonrandomized approach is the major shortcom-
ing of this study. We could not assess power a priori because of the ret-
rospective nature of the study [20]. The deidentiﬁed database created
for this study did not include data on failed induction, need for surgical
intervention to remove placenta or length of time from starting
gemeprost to delivery. We could not power the study for the uncom-
mon outcome of uterine rupture. More than half of the uterine ruptures
(5/9) occurred in 2010–2011. The analysis had very limited power to
detect differences unless such differences had been very large.
In our cohort, the uterine rupture incidence inwomenwith prior ce-
sarean delivery was higher than those reported by two large systematic
reviews on this topic [13,14]. These studies reported uterine rupture in-
cidence of 0.3% and 0.4% in women with prior cesarean delivery under-
going second-trimester medical abortion. Only one study reported data
on uterine rupture after use of gemeprost in patients with prior cesar-
ean delivery, with 1 rupture occurring out of 111 subjects [15]. The rea-
sons for these discrepancies are not completely clear [21]. Misoprostol
may be associated with lower rate of uterine rupture than gemeprost.
If gemeprost increases risk of uterine rupture, offering misoprostol at
our institution may improve patient outcomes. It may be in the best in-
terest of patients to attempt to get misoprostol on formulary at ourTable 2
Annual number of second-trimester medical abortions and number of patients with prior
cesarean delivery, uterine rupture and hysterectomy each year at University of Naples
Federico II
Second-trimester
abortion, n
Prior cesarean
delivery, n (%)
Uterine
rupture, n
Hysterectomy,
n
2007 274 25 (9.8) 1 1
2008 253 46 (18.1) 0 0
2009 254 45 (17.7) 1 1
2010 280 44 (15.7) 3 0
2011 244 47 (19.2) 2 0
2012 162 40 (24.6) 1 0
2013 187 54 (28.8) 1 0
2014 160 39 (24.3) 0 0
Total 1814 340 (18.7) 9 2
Table 3
Individual patient details of the nine women who experienced uterine rupture after second-trimester medical abortion at University of Naples Federico II
Group Year Maternal age (years) Gestational age at abortion (weeks) Hysterectomy Admission to ICU
Case 1 Gemeprost alone 2007 29 17.4 Yes Yes
Case 2 Gemeprost alone 2009 30 19.5 Yes Yes
Case 3 Gemeprost alone 2010 33 20.1 No No
Case 4 Gemeprost alone 2010 34 22.1 No No
Case 5 Gemeprost alone 2010 21 17.8 No No
Case 6 Gemeprost+mifepristone 2011 37 19.5 No No
Case 7 Gemeprost+mifepristone 2011 32 20.3 No No
Case 8 Gemeprost+mifepristone 2012 30 22.7 No Yes
Case 9 Gemeprost+mifepristone 2013 33 23.0 No No
ICU, intensive care unit.
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logue currently available for labor induction abortion in Italy.
Variations in uterine closure at the time of cesareanmay also explain
these differences. In a meta-analysis of randomized trials, Di Spiezio
Sardo et al. reported an increased residual myometrium thickness
when double-layer suture was used at the time of uterine closure
compared to the single-layer suture [7]. At our institution, we most
commonly perform locked continuous single-layer closure of the
hysterotomy.
Finally, should we offer D&E as the ﬁrst-line option for second-tri-
mester abortion? D&E avoids labor, and women may not need to use
prostaglandins ifmifepristone is used in combinationwith osmotic dila-
tors [22]. Evidence suggests that D&E has fewer complications than
labor induction abortion, and patients may prefer D&E [23]. However,
second-trimester D&E is very uncommon in Italy. We suspect that
D&E is a culturally stigmatized procedure and offering D&E as ﬁrst-
line treatment requires substantial education and culture change.
The discovery of the antiprogestin mifepristone in 1980 advanced
nonsurgical methods for abortion and increased the availability of abor-
tion in a variety of healthcare settings. To date, nearly 50 countries have
approved mifepristone for medical abortion. However, mifepristone
alone is not sufﬁcient, and the most effective and safest regimens re-
quire the use of a prostaglandin analogue after mifepristone. Pretreat-
ment with mifepristone increases the complete expulsion rate of
prostaglandin alone from approximately 70% to more than 90% and de-
creases time to expulsion by up to 50% [2,24]. Furthermore, adding mi-
fepristone to the prostaglandin-only regimen reduces prostaglandin
doses, thereby reducing side effects and improving the patient
experience [2,24,25].
In 2011, the International Federation of Gynecology and Obstetrics
Working Group on the Prevention of Unsafe Abortion and its Conse-
quences suggested that pretreatment with mifepristone may reduce
the risk of uterine rupture. They acknowledged that this is a rare compli-
cation [21]. Our data did not support this statement, reporting similar
incidence of uterine rupture inwomen receiving pretreatmentwithmi-
fepristone compared to those who did not.
In summary, our study shows that uterine rupture is a rare compli-
cation of second-trimester medical abortionwith gemeprost. Use of mi-
fepristone prior to gemeprost does not affect this risk.References
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